Library · Metabolic & weight · Treatment of type 2 diabetes mellitus
Dulaglutide (Trulicity)
LY2189265, Trulicity
Long-acting GLP-1 receptor agonist (Trulicity), approved in 2014, pairing a modified GLP-1 sequence with an IgG4 Fc fragment for once-weekly dosing. Improves blood sugar, promotes weight loss, and reduces cardiovascular risk in type 2 diabetes.
Research score 95/100. Reference only, not a dose.
Boxed warning: Thyroid C-cell tumors observed
- Blood Sugar Control
- Appetite Suppression
- Cardiovascular Health
- GLP-1 Agonist
- Weight Loss
- Metabolic Enhancement
- US status
- FDA Approved
- Approval
- FDA + EMA Approved
- Evidence
- FDA-approved once-weekly GLP-1 receptor agonist. Significantly reduces HbA1c and major adverse cardiovascular events (MACE) in Type 2 Diabetes.
- Research score
- 95 / 100
- Indication
- Type 2 Diabetes Mellitus
- Origin
- USA
- Source category
- Digestive System
- Status group
- Approved / prescription
Mechanism
Activates GLP-1 receptors on pancreatic beta cells via cAMP/PKA and PI3K/Akt signaling, boosting glucose-dependent insulin release, cutting glucagon, and slowing gastric emptying; the Fc fragment extends its half-life to about five days, and central GLP-1 activation raises satiety.
Safety file
Boxed warning for thyroid C-cell tumors (from animal data); GI effects (nausea, diarrhea, vomiting) are common, with risks of pancreatitis, kidney injury, and gallbladder disease.
- Nausea
- Vomiting
- Diarrhea
- Abdominal Pain
- Decreased Appetite
- Injection Site Reactions